Showing results (221-230 of 248) with videos related to

Sort By:
Pageof 25
British Journal of Haematology|November 9, 2018
Efficacy of bendamustine and rituximab in splenic marginal zone lymphoma: results from the phase II BRISMA/IELSG36 studyEmilio Iannitto, Monica Bellei, Sandy Amorim, et al.
Blood Advances|January 14, 2025
Large clones of clonal hematopoiesis affect outcome in mantle cell lymphoma: results from the FIL MCL0208 clinical trialSimone Ragaini, Anna Galli, Elisa Genuardi, et al.
Leukemia|August 13, 2020
Outcomes in first relapsed-refractory younger patients with mantle cell lymphoma: results from the MANTLE-FIRST studyCarlo Visco, Alice Di Rocco, Andrea Evangelista, et al.
Clinical Lymphoma, Myeloma & Leukemia|June 26, 2025
Health-Related Quality of Life With Odronextamab Monotherapy for Relapsed/Refractory Follicular Lymphoma in the ELM-2 StudyBenoit Tessoulin, James Harnett, Seok-Goo Cho, et al.
Oncotarget|May 29, 2018
Italian real life experience with ibrutinib: results of a large observational study on 77 relapsed/refractory mantle cell lymphomaAlessandro Broccoli, Beatrice Casadei, Alice Morigi, et al.
Lancet (London, England)|May 5, 2024
Ibrutinib combined with immunochemotherapy with or without autologous stem-cell transplantation versus immunochemotherapy and autologous stem-cell transplantation in previously untreated patients with mantle cell lymphoma (TRIANGLE): a three-arm, randomised, open-label, phase 3 superiority trial of the European Mantle Cell Lymphoma NetworkMartin Dreyling, Jeanette Doorduijn, Eva Giné, et al.
The Journal of Experimental Medicine|August 15, 2012
The coding genome of splenic marginal zone lymphoma: activation of NOTCH2 and other pathways regulating marginal zone developmentDavide Rossi, Vladimir Trifonov, Marco Fangazio, et al.
Blood|December 1, 2010
Genome-wide DNA profiling of marginal zone lymphomas identifies subtype-specific lesions with an impact on the clinical outcomeAndrea Rinaldi, Michael Mian, Ekaterina Chigrinova, et al.
British Journal of Haematology|July 17, 2021
COVID-19 elicits an impaired antibody response against SARS-CoV-2 in patients with haematological malignanciesFrancesco Passamonti, Alessandra Romano, Marco Salvini, et al.
Blood Advances|June 5, 2023
A Fondazione Italiana Linfomi cohort study of R-COMP vs R-CHOP in older patients with diffuse large B-cell lymphomaAnnalisa Arcari, Lugi Rigacci, Alessandra Tucci, et al.
Pageof 25